Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05001516 · ClinicalTrials.gov registry record · Phase 1
Study of Turning Point Therapeutics LM-302 in Patients With Advance Solid Tumors
A Phase 1 study, sponsored by Turning Point Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
NCT05001516: Completed Phase 1 study, sponsored by Turning Point Therapeutics.
NCT05001516 is a Phase 1 study that has completed, run by Turning Point Therapeutics. The registered enrollment target is 17 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (72% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05001516, a Phase 1 study, has completed, sponsored by Turning Point Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
A Phase I, First-in-Human, Open-Label, Dose Escalation and Expansion Study of LM-302 in Patients with CLDN18.2-Positive Advanced Solid Tumors
Primary Outcome
DLT is defined as a toxicity (adverse event at least possibly related to LM302) occurring during the DLT observation period
Interventions
- DRUG LM-302
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2021-12-29 |
| Est. Completion | 2024-01-04 |
| Phase | Phase 1 |
What the finished NCT05001516 record still lists
NCT05001516 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 17 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (72% lower).
The record links to 0 conditions, and to 1 intervention - of which LM-302 is the first listed.
NCT05001516 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05001516 about?
NCT05001516 is a clinical study titled "Study of Turning Point Therapeutics LM-302 in Patients With Advance Solid Tumors". A Phase I, First-in-Human, Open-Label, Dose Escalation and Expansion Study of LM-302 in Patients with CLDN18.2-Positive Advanced Solid Tumors
What is the current status of trial NCT05001516?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2021-12-29. Estimated completion is 2024-01-04.
What interventions are being tested in trial NCT05001516?
The interventions under investigation include: LM-302 (DRUG).
Who is sponsoring clinical trial NCT05001516?
This trial is sponsored by Turning Point Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05001516's enrollment target sits among peer trials
17 1785th of 2000 higher than 215 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02090140 · 17 participants · NA
Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects
- NCT03317860 · 17 participants · NA
Improving Measurement and Treatment of Post-stroke Neglect
- NCT04356469 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
- NCT04414046 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI